Pitcairn’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-9,984
Closed -$450K 77
2025
Q3
$450K Sell
9,984
-20,260
-67% -$946K 0.04% 371
2025
Q2
$1.4M Sell
30,244
-26,174
-46% -$1.28M 0.09% 207
2025
Q1
$3.44M Buy
56,418
+1,697
+3% +$98.9K 0.21% 93
2024
Q4
$3.1M Buy
54,721
+5,763
+12% +$322K 0.18% 100
2024
Q3
$2.53M Sell
48,958
-1,031
-2% -$48.4K 0.15% 127
2024
Q2
$2.08M Buy
49,989
+1,739
+4% +$77.8K 0.13% 150
2024
Q1
$2.62M Buy
48,250
+29,128
+152% +$1.48M 0.17% 115
2023
Q4
$981K Sell
19,122
-9,895
-34% -$519K 0.07% 243
2023
Q3
$1.68M Sell
29,017
-6,027
-17% -$369K 0.14% 135
2023
Q2
$2.24M Sell
35,044
-15,361
-30% -$1.03M 0.19% 100
2023
Q1
$3.49M Buy
50,405
+6,729
+15% +$475K 0.32% 48
2022
Q4
$3.14M Buy
43,676
+2,685
+7% +$202K 0.31% 61
2022
Q3
$2.91M Buy
40,991
+7,919
+24% +$574K 0.32% 59
2022
Q2
$2.55M Buy
33,072
+6,625
+25% +$505K 0.27% 74
2022
Q1
$1.93M Buy
26,447
+5,115
+24% +$343K 0.17% 108
2021
Q4
$1.33M Sell
21,332
-1,277
-6% -$74.9K 0.09% 170
2021
Q3
$1.34M Sell
22,609
-3,237
-13% -$213K 0.09% 161
2021
Q2
$1.73M Buy
25,846
+6,021
+30% +$393K 0.12% 122
2021
Q1
$1.25M Sell
19,825
-4,351
-18% -$271K 0.09% 164
2020
Q4
$1.5M Buy
24,176
+182
+0.8% +$11.2K 0.11% 121
2020
Q3
$1.45M Sell
23,994
-456
-2% -$27.4K 0.12% 109
2020
Q2
$1.44M Sell
24,450
-6,460
-21% -$386K 0.14% 97
2020
Q1
$1.72M Buy
30,910
+2,979
+11% +$182K 0.2% 75
2019
Q4
$1.79M Buy
27,931
+4,586
+20% +$263K 0.17% 83
2019
Q3
$1.18M Buy
23,345
+1,650
+8% +$77.5K 0.12% 110
2019
Q2
$984K Sell
21,695
-642
-3% -$29.9K 0.1% 132
2019
Q1
$1.06M Buy
22,337
+6,006
+37% +$299K 0.12% 108
2018
Q4
$849K Sell
16,331
-5,625
-26% -$302K 0.09% 129
2018
Q3
$1.36M Buy
21,956
+6,276
+40% +$372K 0.14% 98
2018
Q2
$867K Sell
15,680
-381
-2% -$20.6K 0.09% 149
2018
Q1
$1.02M Sell
16,061
-279
-2% -$17.9K 0.11% 118
2017
Q4
$1M Buy
16,340
+185
+1% +$11.6K 0.1% 143
2017
Q3
$1.03M Buy
16,155
+132
+0.8% +$7.71K 0.12% 121
2017
Q2
$893K Sell
16,023
-6,339
-28% -$345K 0.11% 132
2017
Q1
$1.22M Sell
22,362
-133
-0.6% -$7.29K 0.15% 106
2016
Q4
$1.31M Sell
22,495
-664
-3% -$36.3K 0.16% 94
2016
Q3
$1.25M Sell
23,159
-34,811
-60% -$2.24M 0.16% 99
2016
Q2
$4.26M Buy
57,970
+8,510
+17% +$601K 0.55% 21
2016
Q1
$3.16M Sell
49,460
-5,899
-11% -$372K 0.4% 29
2015
Q4
$3.81M Buy
55,359
+442
+0.8% +$29.2K 0.42% 29
2015
Q3
$3.25M Buy
54,917
+17,481
+47% +$1.11M 0.43% 26
2015
Q2
$2.49M Buy
37,436
+1,696
+5% +$112K 0.29% 63
2015
Q1
$2.31M Buy
35,740
+2,785
+8% +$174K 0.25% 70
2014
Q4
$1.95M Buy
32,955
+16,574
+101% +$935K 0.21% 90
2014
Q3
$839K Sell
16,381
-104
-0.6% -$5.2K 0.09% 170
2014
Q2
$800K Sell
16,485
-21
-0.1% -$1.03K 0.09% 181
2014
Q1
$857K Sell
16,506
-5,316
-24% -$283K 0.1% 168
2013
Q4
$1.16M Buy
21,822
+5,006
+30% +$255K 0.13% 135
2013
Q3
$778K Sell
16,816
-454
-3% -$19.9K 0.1% 163
2013
Q2
$772K Buy
+17,270
New +$750K 0.1% 183

Other funds holding BMY

Pitcairn's BMY Position: Q4 2025 in Review

Pitcairn sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 9,984 shares — an estimated $450K sold.

Pitcairn first reported a position in BMY in Q2 2013 and held it in 50 quarters. The position peaked at $4.26M in Q2 2016. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Pitcairn reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Pitcairn sold 9,984 Bristol-Myers Squibb shares in Q4 2025, an estimated $450K.
  • Pitcairn first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 50 quarters.
  • Pitcairn's Bristol-Myers Squibb position peaked at $4.26M in Q2 2016.
  • 2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.